Pulmonx (LUNG) stock

Valves for emphysema , market cap $111M

Minimally invasive valves for emphysema

Worth $111M

$2.80

0.00%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Below Average

In its industry

#45of 84

Medical Devices

Checks firing

6of 14

Trending up

From 52-week high

-13.8%

under its best in a year

LUNG's Quality Score rose 1 point on Tue, Nov 10, to 5. A loss of $43M over the last four quarters, less than the $57M lost a year earlier.

See LUNG's 14 chart checksSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why LUNG rose on Oct 28

Up 27% on Oct 28, and still 41% over its Oct 27 close.

Its Oct 27 results: international revenue was $7.9M, up 5%; net loss narrowed to $8.4M, from $14.0M a year before. It rose 27% on Oct 28.

Sources: Price history, Oct 28, 2026; Company release, Oct 27, 2026

1 more reason, free with an account →3 more reasons why LUNG rose on Oct 28, from its filings, with the timeline and its peers, for Pro members.

Key facts on LUNG

Key facts on LUNG
Holding it back	Moves 9.7% a day with no profit behind it
Latest filing	10-Q, Nov 3 Filed its quarterly report (10-Q) for the quarter to Sep 30, 2026

1 more reason behind LUNG's 5, free with an account →3 more reasons behind LUNG's 5, for Pro members.

What's next

Wed Nov 11: Canaccord Genuity 20th Annual…Investor conference · date confirmed.

1 more date ahead: the conference, for Pro members.

LUNG catalysts

Coming up

After its last 4 reports it closed +18.6% on average, higher 4 of 4 times.

Why LUNG scores 5

Below Averagefor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means

+6Chart checks 6 of 14 firing right now, one point each
+2Run-up 117% over 6 months

Long-term trend adds
Size subtracts
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Profit, Growth, Dilution, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on LUNG and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:45 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when LUNG's Quality Score turns up

A free account. No card.

How LUNG ranks in Medical Devices

LUNG is #45 of 84 by Quality Score.

How LUNG ranks in Medical Devices
Rank	Stock	Checks	Quality Score
1	DCTHDelcath Systems	7/14	22
2	EWEdwards Lifesciences	7/14	19
3	WSTWest Pharmaceutical Services	7/14	18
	LIVNLivaNova		Open for its score
	LMATLeMaitre Vascular		Open for its score
	MDLNMedline		Open for its score
	MDTMedtronic		Open for its score
45	LUNGPulmonx	6/14	5

When does LUNG report earnings, and what happens after?

Expected to report Wed Feb 17, after the close (in 99 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What LUNG reported on Oct 27, 2026

The quarter

Sales of $22.8M, 6% more than a year ago; a loss of $0.19 a share, from $0.34.

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

LUNG's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year 2026
Gross margin	about 77%raised

Figures as filed (SEC filing, Oct 27)

3 more outlook lines, for Pro members.

The numbers

Market value: $111M; today
Sales: $88.8M; down 3.1% on the year
Free cash flow: -$25.6M; last 12 months

Sales grew 19% a year over 3 years, fiscal 2022 to 2025.

Its share count grew 3.1% a year over 3 years.

4 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on LUNG: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 4

+11.8%+6.7%+28.8%+27.3%

Mar 4Apr 29Jul 29Oct 27

Reported	When	Gap	Reaction	5 days
Oct 27, 2026After close	After close	+19.7%	+27.3%	+37.4%
Jul 29, 2026After close	After close	+12.0%	+28.8%	+58.4%
Apr 29, 2026After close	After close	-1.7%	+6.7%	+7.5%
Mar 4, 2026After close	After close	+0.7%	+11.8%	+24.6%

LUNG closed higher after 4 of its last 4 reports.

LUNG sales and profit by year

Sales and profit by year

Sales grew every year from 2018 to 2025, to $90.5M. It lost money in each of the eight years.

LUNG has 6 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on LUNG, and all 14 on every stock.Get in free →

LUNG RSI today: 62.6, above its 50-day and 200-day averages

Not scored

RSI 62.6, MACD above signal, above both averages. Not scored.13 readings

The deep dive on LUNG

What it does and how it makes money5 findingsAn operating loss of $53.7M in fiscal 2025, on $90.5M of sales.Annual report, filed Mar 10, 2026"Our patents expire between 2026 and 2042." (10-K for fiscal 2025)SEC filing · Mar 10, 2026
Where it stands5 findingsFor Pro members5 findings on where LUNG stands: its cash, debt, and share count, for Pro members
What changed in its filings4 findingsNew in its "Risk Factors" this year: "On March 2, 2026, we entered into a Credit Agreement and Guaranty (as amended, the 'Perceptive Credit Agreement') with the subsidiary guarantors party thereto from time to time, the lenders party thereto from time to time, and Perceptive Credit Holdings V, LP ('Perceptive') …" (10-K for fiscal 2025)SEC filing · Mar 10, 2026, against the one of Feb 25, 2025
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades LUNG, for Pro members

14 more findings on LUNG, each with its source, for Pro members.

LUNG insider trades

4 insiders sold $321K across 29 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellGlendon E. French III$85KPresident and CEOat $2.26 on Sep 1, filed Sep 3

SellGlendon E. French IIIPresident and CEO$85Kat $2.26 on Sep 1, filed Sep 3

All 29 insider filings on LUNG from the last six months, for Pro members.

LUNG's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Glendon E. French IIIPresident and CEO · 5 trades
David Aaron LehmanGeneral Counsel · 8 trades
Geoffrey Beran RoseChief Commercial Officer · 8 trades
Srikanth RadhakrishnanChief Science & Techn. Officer · 8 trades

See insider trades by person

Which ETFs hold LUNG?

In ETFs: LUNG is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Pulmonx

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

296 employeesRedwood City, CApulmonx.com

What Pulmonx says it competes with

“Our industry is highly competitive and subject to rapid change from the introduction of new products and technologies and other activities of industry participants.”

From its annual report, SEC filing · Mar 10, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on LUNG and every other stock.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn LUNG's score around: 7 things
2 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaySep 3Glendon E. French III sold LUNG$85K at $2.26, filed Sep 3

Alerts are optional.

See LUNG's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: LUNG's Quality Score is 5 (Below Average), #45 of 84 in Medical Devices. Insiders sold $321K in the last 6 months (Form 4).

What does LUNG's Quality Score say?

LUNG scores 5 today, which Breakaway calls Below Average. It is #45 of 84 in Medical Devices by Quality Score, with 6 of 14 chart checks firing. Up 27% on Oct 28, and still 41% over its Oct 27 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is LUNG's Quality Score?

LUNG scores 5 today, which Breakaway calls Below Average (0 to 5). That is #45 of 84 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind LUNG's 5.

Are insiders buying LUNG?

4 insiders sold $321K across 29 filings in the last 6 months. No open-⁠market buys on record. The newest is Glendon E. French III, President and CEO, who sold $85K on Sep 1. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.